You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《復牌公告》泰凌醫藥(01011.HK)現金加新股收購上海漢都52%
阿思達克 07-11 04:47

泰凌醫藥(01011.HK)公布,向WD Investment收購新藥研發公司---上海漢都40%股權,初始代價3.12億元,將透過發行4.27億股代價股支付,發行價0.73元,較停牌前折讓2.67%。同時,以現金代價3,000萬美元認購上海漢都新股及可換股債券。完成後,公司共計持有上海漢都52%權益。

此外,公司將視乎市況配售不超過3.8億股新股,每股作價0.73元,集資總額約2.78億元。

上海漢都已研發若干具有自主知識產權、技術壁壘高的載藥技術平台,開發解決未滿足醫學需求的創新藥,主要以帕金森治療為核心。完成後,WD Investment及其一致行動人士共計持有公司擴大後股本38%。

公司股份申請周四(11日)恢復買賣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account